Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Adenoviral vector-based vaccine against enterovirus infection

An enterovirus and recombinant adenovirus technology, applied in the field of immunity, can solve the problems of inducing immunogenicity and obstruction

Active Publication Date: 2017-05-31
NAT INST OF HEALTH REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES NAT INST OF HEALTH
View PDF12 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, proteins of VLPs produced by non-human cells with different subsequent modifications (such as glycation) may induce different immunogenicity in humans
In addition, there are obstacles in the production of highly purified VLPs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adenoviral vector-based vaccine against enterovirus infection
  • Adenoviral vector-based vaccine against enterovirus infection
  • Adenoviral vector-based vaccine against enterovirus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0082] In this study, we have designed and genetically engineered a recombinant adenoviral vector, Ad-EVVLP, carrying EV71P1 and 3CD genes, which were inserted into the E1 / E3 deleted adenoviral genome. Ad-EVVLP can be produced in HEK-293A cells. In addition to Ad-EVVLP particles, virus-like particles (VLP) are formed by physically linking with EV71-type capsid proteins VPO, VP1 and VP3; wherein these capsid proteins are the products of the P1 gene. The virus particles were cleaved by 3CD protease and confirmed to be produced by Ad-EVVLP-producing cells, and identified by transmission electron microscopy and western blotting. Immunogenicity studies in mice showed that Ad-EVVLP-immunized antisera can neutralize EV71 type B4 and C2 genotypes. VLP-specific CD4 + and CD8 + Activation of / IFN-γ T cells is associated with the induction of Th1 / Th2-balanced IFN-, IL-17, IL-4, and IL-13; in contrast, FI-EV71 only induces Th2-mediated neutralization Antibody against EV71 and low VLP-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates to a recombinant adenoviral vector for generating immunity against enterovirus infection. In one embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a PI protein and a 3 CD protease of an enterovirus. In another embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a 3C protease or a 3CD protease of an enterovirus. The present invention also relates to a vaccine composition comprising the recombinant adenoviral vector as described. A method of inducing an immune response in a subject against enterovirus infection using the recombinant adenoviral vector and the vaccine composition is provided. Further provided is a method for producing virus like particles of an enterovirus by expressing the adenoviral vector as described herein in mammalian cells.

Description

[0001] Related applications [0002] This case is based on 35 U.S.C. §119(e), claiming priority based on U.S. Provisional Patent Application No. 61 / 985,803 filed on April 29, 2014, the entire contents of which are incorporated herein by reference. technical field [0003] The present invention relates generally to the field of immunization and, in particular, to adenoviral vector-based vaccines against enteroviral infections. Background technique [0004] Enteroviruses, belonging to the Picornaviridae family, are tiny, non-enveloped viruses containing positive strand RNA. The Enterovirus genus now includes 12 species: Enterovirus A, Enterovirus B, Enterovirus C, Enterovirus D, Enterovirus E, Enterovirus F, Enterovirus G, Enterovirus H, Enterovirus J, Rhinovirus A, Rhinovirus Virus B and rhinovirus C. These viruses infect the intestinal tract, but can cause various types of diseases. Typical enteroviral diseases are meningitis, paralysis, myocarditis, hand, foot and mouth ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/12A61K38/00
CPCA61K39/12A61K2039/5252A61K2039/542A61K2039/55566C12N2710/10323C12N2710/10343C12N2770/32334C12N2770/32371Y02A50/30A61K39/125C12N15/86C12N2770/32323A61K2039/545A61K2039/5256A61K2039/5258A61K2039/57C12N2770/32351
Inventor 周彦宏邹岳良庄再成
Owner NAT INST OF HEALTH REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES NAT INST OF HEALTH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com